Scope: Wakame is an edible seaweed that is a common constituent in the Japanese diet. Previous studies showed that wakame consumption is associated with the prevention of metabolic syndrome, but the molecular mechanisms underlying the protective effects are poorly understood. Methods and results: To determine if the expression of hepatic genes is affected by ingestion of the brown seaweed Undaria pinnatifida (wakame), rats were fed a diet containing 0, 0.1, or 1.0 g per 100 g dried wakame powder for 28 days. Administration of 1% wakame significantly decreased serum total cholesterol levels. Hepatic gene expression was investigated using DNA microarray analysis, and the results showed that wakame suppresses the lipogenic pathway by downregulating SREBF-1. Moreover, bile acid biosynthesis and gluconeogenesis were promoted by upregulation of the PPAR signaling pathway, which leads to a reduction in the accumulation of cholesterol and promotion of β-oxidation. Conclusions: These results suggest that wakame ingestion affects glucose and lipid metabolism by altering the expression of SREBF-1 and PPAR signal-related genes.
Introduction
Seaweed is a unique foodstuff and an important component of the Japanese diet. The brown seaweed Undaria pinnatifida (wakame) is rich in several minerals, vitamins, and dietary fiber, and is one of the most popular seaweeds used in the traditional Japanese diet. Wakame contains several components that exhibit various biological activities, including anticancer effects, [1] dioxin excretion, [2] and antihypertensive, [3] and antiviral effects. [4] In clinical trials, wakame displayed beneficial effects as a supplemental regimen for the prevention of hypertension and metabolic syndrome. [5] People in Japan with an average life expectancy of 83.7 years continue to outlive people in other parts of the world, according to the World Health Organization report released in 2017. The westernization of eating habits is believed to be one of the main causes of the worldwide rise in metabolic syndrome, and consequently the traditional Japanese diet has received considerable attention since the 1960s due to its association with an extremely low rate of coronary heart disease, the major cause of death during the past decade throughout the world. [6, 7] In addition, it was reported that elderly Japanese individuals who consume more seaweed have lower blood pressure [8] and take fewer medications for hypertension than individuals with a lower seaweed intake. [9] In the present study, we show that daily consumption of wakame may contribute to health. In addition, to investigate the mechanism by which wakame exerts its anti-obesity effects, we examined the influence of wakame consumption in rats using DNA microarray technology.
Experimental Section

Animals and Diets
Animal experiments including sampling of blood and liver, and measurement of serum biochemical parameters were outsourced to Oriental Yeast Co., Ltd. (Tokyo, Japan). Male Sprague Dawley (SD) rats aged 4 weeks were housed in a www.advancedsciencenews.com www.mnf-journal.com temperature-controlled room with a 12 h light-dark cycle. Animals were allowed free access to drinking water and were fed a diet prepared in accordance with the recommendations of the American Institute of Nutrition (AIN-93G). [10] After acclimatization to the environment and to investigators for 1 week, rats were fed purified experimental diets. Rats were divided into three groups (n = 6, three rats per cage) and fed a control or a wakame diet consisting of the control diet supplemented with the indicated amount of wakame powder. Wakame flake were washed with 20% ethanol for 30 min, dried, and milled. The constituents of wakame powder were 26.9% protein, 5.6% fat, 0.1% carbohydrate, 50.7% fiber, and 12.6% ash. Animals were fed these diets for 28 days. On the final day of the experiment, livers were excised from each animal and submerged in RNALater (Life Technologies, Carlsbad, CA) overnight at 4°C and stored at −80°C until RNA isolation. Total RNA was used for microarray analysis.
All animal experiments were approved by the Animal Care Committee of Oriental Yeast Co., Ltd. and followed the Committee Guidelines for the Care and Use of Laboratory Animals (11009).
DNA Microarray Analysis
Total RNA was extracted from the liver and DNA microarray analysis was performed with GeneChip 3ʹ IVT Express Kit (Affymetrix, Santa Clara, CA) and GeneChip Rat Genome 230 2.0 Array (Affymetrix), as previously described. [11] All experimental procedures were performed according to the manufacturer's instructions. All microarray data were MIAME compliant and have been deposited in a MIAME compliant database, specifically the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/, under GEO Series accession number GSE89347), as detailed on the FGED Society website (http://fged.org/projects/miame/).
Affymetrix GeneChip Command Console (AGCC) software was used to reduce the array images to the intensity of each probe (CEL files). CEL files were quantified with the Factor Analysis for Robust Microarray Summarization (FARMS) algorithm [12] using statistical language R [13] and Bioconductor. [14] Differentially expressed genes (DEGs) were identified by applying the rank products method. [15] Probe sets presenting a false discovery rate (FDR) <0.05 were regarded as having significantly different expression levels between the two groups.
Gene Ontology Analysis
Gene annotation enrichment analysis of selected probes was performed using a web-based functional annotation tool at the Database for Annotation, Visualization, and Integrated Discovery (DAVID; http://david.abcc.ncifcrf.gov/). The Benjamini and Hochberg FDR was used to correct for multiple tests. A Gene Ontology (GO) term with a FDR-corrected p-value < 0.05 was considered to be significantly enriched. The online analysis application QuickGO (https://www.ebi.ac.uk/QuickGO/) was used to determine the hierarchical structure of the enriched GO terms. [16] 
Blood analysis
Blood was collected from the postcaval vein, and serum was prepared by centrifugation. Serum triglycerides (L-type wako TG·H, Wako, Tokyo, Japan), total cholesterol (L-type wako CHO·H, Wako), nonesterified fatty acids (NEFA-SS "Eiken," Eiken, Tochigi, Japan), and glucose (Quick-Auto Neo GLU-HK, Shinotesuto, Kanagawa, Japan) were analyzed using commercially available kits.
Statistical Analysis
All data are expressed as means ± SE. Statistical analyses between multiple groups were determined by one-way ANOVA followed by Dunnett's test.
Results
Wakame Consumption Decreases Serum Total Cholesterol Levels
No significant changes in food intake or body weight gain were observed between control and treated rats (p > 0.05 each). Total cholesterol levels in the serum of rats treated with 1% wakame were significantly decreased compared with those in the control group (Table S1 , Supporting Information).
DNA Microarray Data Quantification and Detection of DEGs
To characterize the mechanism underlying the effects observed in the wakame group, we focused on differences in the overall hepatic gene expression patterns of wakame-fed rats. Four samples were chosen from each group based on average body weight and serum cholesterol levels, and subjected to DNA microarray analysis. Principal component analysis revealed that samples from the 1% wakame group and the control group displayed distinct differences in gene expression (Figure 1) . Consistently, the 0.1% wakame group exhibited an intermediate profile between the control group and the 1% wakame group.
For a comprehensive understanding of the effect of wakame administration on the liver, we extracted DEGs using the rank products method. Statistical analysis of the GeneChip data revealed that the expression of 1077 and 485 probe sets in the Rat Genome 230 2.0 Array was significantly altered after 28 days of 1% or 0.1% wakame administration, respectively. Of the 1077 probe sets altered in response to the 1% wakame diet, 513 were upregulated and 564 were downregulated. Of the 485 probe sets altered in response to the 0.1% wakame diet, 348 were upregulated and 137 were downregulated. In addition, 221 upregulated probe sets overlapped between the 1% and 0.1% wakame groups, while 114 downregulated probe sets overlapped between the 1% and 0.1% wakame groups ( Figure S1 , Supporting Information). Indeed, most of the genes that were affected by 0.1% wakame administration overlapped with genes in the 1% wakame group. 
GO Analysis
To gain insight into the effects of wakame on the gene expression profile, we examined which gene function categories were overrepresented among DEGs. Accordingly, the extracted 1077 probe set in the 1% wakame group and the 485 probe set in the 0.1% wakame group were analyzed by gene annotation enrichment analysis using DAVID. GO terms with FDR-corrected p-values of less than 0.05 were applied to QuickGO to map the terms hierarchically (Figure 2 ; Figure S2 , Supporting Information).
In the group consuming a 1% wakame diet, the specific overrepresented GO terms (i.e., GO terms appearing in the deepest hierarchical level) were "fatty acid metabolic process," "cholesterol biosynthetic process," "gluconeogenesis," and "pyruvate metabolic process." Significantly overrepresented GO terms were generally related to energy metabolism in the 1% wakame group (Figure 2) , and similar GO terms were significantly overrepresented in the 0.1% wakame group ( Figure S2 , Supporting Information). The GO terms "fatty acid metabolic process," "gluconeogenesis," and "pyruvate metabolic process" commonly appeared in the deepest hierarchical level in both treatment groups. Therefore, we subsequently focused on DEGs related to fatty acid, cholesterol, and glucose metabolism.
Genes that were significantly affected by ingestion of wakame and those associated with fatty acid, cholesterol, and glucose www.advancedsciencenews.com www.mnf-journal.com Table 1 . Differentially expressed genes related to energy metabolism that is altered in the rat liver following consumption of a 1% wakame diet. metabolism are listed in Table 1 . Genes encoding 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the rate-limiting enzyme in cholesterol biosynthesis, and 7-dehydrocholesterol reductase (DHCR7) were significantly downregulated in the 1% wakame group. Consistent with these observations, we found that serum cholesterol levels were decreased in the 1% wakame group (Table S1 , Supporting Information). Furthermore, expression of the gene encoding sterol regulatory element-binding transcription factor 1 (SREBF-1), a transcription factor promoting the transcription of enzymes required for lipogenesis, was significantly downregulated in the 1% wakame group. SREBF-1 directly stimulates the transcription of genes that encode key enzymes involved in fatty acid synthesis such as acetyl-CoA carboxylase α (ACACA) and fatty acid synthase (FASN), both of which were downregulated in the 1% wakame group. In addition to fatty acid metabolism, genes related to β-oxidation, including carnitine palmitoyltransferase 1a (Cpt-1a) and acyl-CoA oxidase 2 (Acox2), were upregulated.
Regarding glucose metabolism, gluconeogenesis was upregulated in the 1% wakame group. By contrast, glycolysis-related genes such as pyruvate kinase, liver, and RBC (Pklr) and glucose-6-phosphate dehydrogenase (G6pd) were downregulated in the 1% wakame group.
To identify significantly enriched pathways, we also assessed Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in DAVID using the 1% wakame group microarray data (p < 0.05). KEGG pathways identified as enriched based on upregulated genes included the "PPAR signaling pathway" (p = 1.08 × 10 −3 ) and the "Primary bile acid biosynthesis pathway" (p = 1.75 × 10 −2 ). Meanwhile, the "Steroid biosynthesis pathway" (p = 2.56 × 10 −2 ) was identified based on downregulated genes. The peroxisome proliferator-activated receptor (PPAR) family of nuclear receptors regulates several biological pathways. In our experiments, several genes related to the PPARα pathway were notably affected by the ingestion of wakame. Consistent with these results, "Primary bile acid biosynthesis" was identified by KEGG enrichment analysis.
Upregulated genes in the PPAR pathway and the primary bile acid biosynthesis pathway that were notably affected by the ingestion of wakame are listed in Table S2 , Supporting Information. With respect to lipid metabolism, cytochrome P450, family 7, subfamily a, polypeptide 1 (Cyp7a1), Acox2, and Cpt-1a were upregulated in the 1% wakame group. In addition, PPARα was significantly increased in the 0.1% wakame group (p = 2.33 × 10 −2 ). With respect to gluconeogenesis, phosphoenolpyruvate carboxykinase 1 (Pck1) and glycerol kinase (Gk) were upregulated in the 1% wakame group. Cyp7a1 and Acox2 were also assigned to the PPARα pathway. Finally, the pathway related to the synthesis of bile acid was predicted to be activated.
Discussion
The results of the present study suggest that long-term intake of wakame significantly activates the PPAR signaling pathway followed by fatty acid β-oxidation, bile acid production, and gluconeogenesis. In addition, a reduction in serum cholesterol was observed at both the biochemical and gene expression levels. Therefore, ingestion of wakame may be used as a potential preventive measure against metabolic syndrome.
SREBF-1, a transcription factor, is a key regulator of the lipogenic pathway. [17] The 1% wakame diet decreased Srebf-1 mRNA levels in the rat liver, suggesting that wakame suppresses the lipogenic pathway by downregulating SREBF-1, which can lead to a reduced accumulation of body fat. In addition, we found that Fasn and Acaca, which are regulated by SREBF-1, were downregulated by wakame ingestion. FASN is a critical metabolic enzyme for lipogenesis that catalyzes the synthesis of saturated fatty acids. [18] The suppression of ACACA, a cytosolic enzyme that catalyzes the carboxylation of acetyl-CoA to form malonylCoA, leads to a reduction in hepatic triglyceride synthesis and accumulation. [19] Similarly, PPARs also play important roles in the regulation of energy metabolism. We observed a significant upregulation of the gene encoding PPARα in the 0.1% wakame group, and a significant upregulation of PPARα-regulated genes, such as Retinoid X receptor α (Rxra), Cpt-1a, Cyp7a1, and Pck1, in both the 0.1% and 1% wakame groups, indicating that wakame ingestion activates the PPARα pathway in the rat liver (Tables S2  and S3 and Figure S3 , Supporting Information). We observed increases in PPARα and Cpt-1a, suggesting that wakame ingestion causes an increase in the oxidation of fatty acids in the liver. Previous reports have indicated that a diet containing at least 2% wakame [20] or marine carotenoid fucoxanthin [21, 22] has anti-obesity effects. The present study is consistent with these findings.
Bile acid biosynthesis, which was altered significantly in the wakame groups, is one of the metabolic pathways regulated by PPAR signaling. In this study, a significant decrease in serum total cholesterol levels was observed in the 1% wakame group (Table S1 , Supporting Information ). Based on the microarray data, we conclude that stimulation of bile acid synthesis is one of the mechanisms by which serum cholesterol is reduced. Expression of CYP7a1, which encodes a key enzyme in cholesterol catabolism that catalyzes the rate-limiting enzyme of bile acid biosynthesis, [23] was upregulated by wakame ingestion. By contrast, the expression of genes encoding enzymes involved in cholesterol biosynthesis including HMGCR was downregulated. These results indicate that wakame ingestion decreases the expression of genes related to cholesterol synthesis and increases the expression of genes related to bile acid synthesis, leading to decreased serum cholesterol levels. Indeed, it is reported that hypercholesterolemia is decreased by wakame ingestion in humans. [5] Interestingly, Sirtuin 3 (Sirt3) was significantly upregulated in the 1% wakame group (FDR = 0.039) in this study. The sirtuins (SIRT1-SIRT7) are a family of nicotinamide dinucleotide (NAD+)-dependent protein deacetylases. SIRT3 is a mitochondrial sirtuin that regulates fatty acid oxidation during fasting and ATP production. [24] Deficiency of SIRT3 accelerates the www.advancedsciencenews.com www.mnf-journal.com development of diseases related to metabolic syndrome in mice. [25] Wakame ingestion may alter energy metabolism to the extent that it resembles the state of starvation.
Overall, the findings of the present study suggest that wakame suppresses the lipogenic pathway by downregulating SREBF-1, which leads to a reduced accumulation of body fat. Moreover, this study suggests that bile acid biosynthesis and gluconeogenesis are increased through the upregulation of genes involved in the PPAR signaling pathway, which leads to decreased accumulation of cholesterol and promotion of β-oxidation (Figure 3) . Moreover, our data indicate that ingestion of 0.1% wakame alters the gene expression pattern in the liver similar to supplementation of 1% wakame. These findings suggest that continuous ingestion of wakame, even at low daily doses, may effectively modulate lipid metabolism, at the mRNA level.
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